Knowledge is power in driving pharma commercialization success
Two Labs is an industry leader in all facets of pharma services. Our professional, experienced team offers a wealth of skills and knowledge to manage the complexities of pharma product commercialization, market access and market intelligence.
Two Labs Acquires CEEK Enterprises
Originally posted on PR Newswire Two Labs Acquires CEEK Enterprises Company enhances services for biopharma clients with CEEK's complementary suite of management consulting expertise COLUMBUS, Ohio, Feb. 6, 2020 /PRNewswire/ -- Two Labs, an industry-leading pharma services company, today [...]
Two Labs’ Acquisition of CEEK Enterprises Featured in Multiple News Outlets
In February of this year, CEEK Enterprises brought to the Two Labs Family a new echelon of specialized expertise in life sciences corporate development, commercial strategy, clinical development and medical affairs. Read more about how the CEEK acquisition added to [...]
Powell businessman Rich Wartel always there to help by donating time, money, advice
Originally posted on Dispatch.com Rich Wartel offers each of his 130 employees at Two Labs $1,500 annually to donate to a cause of their choice or put toward good deeds of their own. The noisy workshop inside the Hilltop nonprofit [...]
Two Labs Makes List Best Places to Work for 2019
Originally posted in Columbus Business First Here are the Best Places to Work for 2019, plus how they keep their people happy About the program The Best Places to Work program is open to any company or organization with a [...]
Current and Future Oncology Management in the United States
Originally posted by the Journal of Managed Care & Specialty Pharmacy Volume 25 Issue (2) Anne Runyan, BA; Jordan Banks, MPA; and Daniele Severi Bruni, MS MKO Global Partners, Powell, Ohio. J Manag Care Spec Pharm, 2019 Feb;25(2):272-281. Abstract BACKGROUND: [...]
NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab
With the recent patent expiry of Humira® (adalimumab) in Europe, NHS England last week published a press release reiterating their goal of realizing £300 million in annual savings through the adoption of best value biologic medicines (originator or biosimilar) by 2021. With more than [...]